Dr Veena Kumari obtained her doctorate in psychology from Banaras Hindu University in India before moving to the Institute of Psychiatry in London, UK, where she most recently served as the Professor of Experimental Psychology. Currently, she is the Chief Scientific Officer for the Sovereign Health Group, USA. Dr Kumari has published over 250 peer-reviewed articles and served as the Associate Editor or Editorial Board Member for a number of journals including Personality and Individual Differences, Schizophrenia Research and Treatment, Psychiatry Research: Neuroimaging, and the Australian and New Zealand Journal of Psychiatry.

Dr. Silva obtained a doctorate (Ph.D.) in Pharmacology from the Federal University of São Paulo (São Paulo, Brazil). Dr. Silva was Adjunct Professor in the Federal University of Rio Grande do Norte from 2006 to 2014, were she established the behavioral neuroscience lab and was deputy coordinator of the Ph.D. Psychobiology Program. Currently, she is an Associate Professor back in the Federal University of São Paulo, coordinating the behavioral neuroscience lab of the Pharmacology Department. She has published about 60 scientific papers in the psychopharmacology and behavioral neuroscience fields.

Dr. Joseph Ben-Sheetrit obtained his MD degree from the Sackler Faculty of Medicine at the Tel Aviv University in Israel. He is a psychiatry resident at the Geha Mental Health Center in Petah Tikva, Israel. He is a member of the Israel Society of Biological Psychiatry. He focuses on ADHD and psychopharmacology and has published studies about ADHD-related impairment and persistent side effects of Selective Serotonin Reuptake Inhibitors (SSRIs).

Domenico De Berardis works as Psychiatrist and Psychotherapist in the "real world" clinical practice at the NHS Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy. He collaborates independently with the Institute of Psychiatry of G. d’Annunzio University Chieti-Pescara, Italy. He completed a post-graduate course in “Addiction Medicine” at the University G. d'Annunzio of Chieti, has attained a Ph.D. in “Functional Neuroimaging” at the Institute for Advanced Biomedical Technologies (ITAB) of the University G. d'Annunzio of Chieti and achieved a master in “Clinical Psychopharmacology” at the Scientific Institute and University Vita-Salute San Raffaele, Milan.

Dr. Blum serves as Chairman of Geneus Sciences LLC., His concept of Reward Deficiency Syndrome is being embraced by world leaders in science and is part of the DSM –V, ASAM, Sage Encyclopedia if Abnormal Psychology. Dr, Blum is credited with the DRD2 gene discovery and addictive diseases. He serves as Editor-in-Chief in Journal of Reward Deficiency Syndrome (he coined) and Addiction Sciences and Co-EIC of Journal of Neuroimaging in Psychiatry and Neurology (USG). He is currently serving on fourteen other prestigious journal’s Editorial Boards. He has published over 450 articles, 16 books, numerous patents and received many awards (Life-Time Achievements) for his seminal discoveries. He is the founding President of United Scientific Group (USG).

Professor Filippo Bogetto was Director of the post-graduate School in Clinical Psychology of the University of Turin, Chief Director of Department of Neuroscience of University of Turin.He was Director of the Psychiatric Unit of the AOU Città della Salute e della Scienza di Torino, Chief Director of the Mental Health Department ASL TO1 - AOU Città della Salute e della Scienza di Torino and Head of the PhD School in Neuroscience at the University of Turin.He is a member of various scientific societies, like the Italian Society of Psychopathology (of which he was President).Professor Bogetto's scientific activity has appeared in hundreds of publications on international and italian scientific journals, in several books, and in proceedings of italian and international congresses and meetings. He has been chairman and organizer of various Italian and international Congresses.

Michel Bourin has held the position of Professor of Pharmacology at the University of Nantes since 1985. After completing his pharmacist and medical training at Tours University he was awarded degrees in neuropsychopharmacology, clinical pharmacology and general pharmacology in Paris and completed his psychiatric training in Nantes. Since 1988, Professor Bourin has been Head of Research : Neurobiology of Anxiety and Depression. He has also served as an Adjunct Professor in the Department of Psychiatry at the University of Edmonton (Alberta) since 1995 and visiting Professor at University of Craiova (Romania). He is Doctor Hononoris Causa of the University of Tartu (Estonia) and University of Craiova (Romania) He is now Psychiatrist in a centre for mental handicapped adults in Montredon (near Narbonne) He has published more than 3000 original papers in the field of psychopharmacology and more than 250 educational/review papers both in French and English.

Dr. Boyd graduated from the University of Illinois at Urbana-Champaign in 1977 with a BS in Physiology. He received a Ph.D in Molecular Biology from the University of Texas at Austin in 1986. After working as a postdoctoral researcher at the University of California, San Diego and the Salk Institute for 4 years, he moved to Ohio State in 1990. He is an Associate Professor in the Department of Neuroscience. Dr. Boyd has also been involved in undergraduate and graduate education for most of his career. He served on the Neuroscience Graduate Studies Program Graduate Studies Committee.

Robert Carey received his Ph.D. in in Psychology from the University of Chicago. He has been a Professor in the Psychiatry department at Brown University and he is currently a Research Professor in the Department of Psychiatry at the Upstate Medical University of New York. Dr. Carey has published approximately 200 peer reviewed research articles. He has received peer reviewed funding for this research from the National Institutes of Health and the Veteran's Administration Merit Review Grant Program.Currently he serves on the editorial boards of several International scientific journals namely, Behavioral Brain Research, the Journal of Neuroscience Methods and Pharmacology , Biochemistry and Behavior.

Dr. Comai is Assistant Professor of Pharmacology at the San Raffaele Vita-Salute University, Milan, Italy, and Adjunct Professor at the Department of Psychiatry, McGill University, Montreal, Canada. Dr. Comai is interested in understanding the role of tryptophan metabolism via serotonin and melatonin but also kynurenine in brain functioning, and subsequently, to determine the extent to which these systems are involved in the etiology and treatment of mental disorders, particularly depression, anxiety, insomnia, and aggressive behaviour. Dr. Comai has received several awards, including the “2015 New Investigator Award” by the American Society of Clinical Psychopharmacology andthe NARSAD Young Investigator Award.

Dr. Duman is Professor of Psychiatry and Neurobiology, Director of the Abraham Ribicoff Research Facilities, and the Jameson Professor of Psychiatry at Yale. Studies from Dr. Duman’s laboratory have contributed to characterization of the molecular and cellular actions of stress, depression, and antidepressant treatments, providing the basis for the neurotrophic and synaptic hypothesis of depression. Dr. Duman has received several awards, including the Anna-Monika Prize, Nola Maddox Falcone Prize, Janssen Prize, NIMH MERIT Award, and a NARSAD Distinguished Investigator Award. He is author of over 300 original articles, reviews and chapters and has given over 250 invited lectures.

Dr. Haleem obtained a doctorate (PhD) in Neurochemistry from the Institute of Neurology, London University. Currently she is working as Meritorious Professor Neuroscience, PCMDICCBS University of Karachi. Actively engaged in teaching and research, Prof Haleem is author of over 200 publications in high impact factor journals, has supervised over 40 PhD & M Phil students and has written text books on topics of neuroscience. Her research centers on the Molecular and Neural basis of stress, depression, anorexia, addiction and memory. Currently, she is Editor-in-Chief of the ‘Journal of ADHD and Care’ and member editorial board of many neuroscience journals.

Dr. Hollander is Director of the Autism and Obsessive Compulsive Spectrum Program and Clinical Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and the Montefiore Medical Center. He is also Director of the Spectrum Neuroscience and Treatment Institute, and Chair of the Advisory Council, ICare4Autism. Formerly, he has served as the Esther and Joseph Klingenstein Professor and Chairman of Psychiatry, Director of the Seaver and Greater NY Autism Center of Excellence, and Director of the Compulsive, Impulsive and Anxiety Disorders Program at Mount Sinai School of Medicine. Prior to then, he was Associate Professor of Psychiatry and Director of the Compulsive and Impulsive Disorders Program at Columbia University College of Physicians and Surgeons.

Professor Hughes holds an MSc degree from the University of Canterbury (where he is currently a Professor of Psychology), and a PhD from the Queen’s University of Belfast. He has worked extensively in animal pre-clinical psychopharmacology with a particular focus on sex differences in responsiveness to therapeutic and recreationally used drugs. Professor Hughes has published over 150 papers in a variety of behavioral and psychopharmacological journals. He was awarded Recipient, Hunter Award from the NZ Psychological Society, 2008, for “outstanding, internationally acclaimed research in psychology”. Recipient, Three Rs Award, from the National Animal Ethics Advisory Committee (New Zealand Ministry of Agriculture and Fisheries), 2007 for “an outstanding contribution to humane science in New Zealand and the practical application of the Three Rs”.

Dr. Peter Illes studied medicine and has been an Associate Professor in the Department of Pharmacology of the University of Freiburg. Later, he became a Full Professor and Director of the Department of Pharmacology at the University of Leipzig, Germany. He has received numerous honors, awards and recognition for his contributions to science overall. Dr. Illes is neuroscientist with special emphasis on two types of ATP-sensitive receptors, belonging to the P2X3 and P2X7 class.

Robert Lalonde completed post-doctoral studies at the Clinical Research Institute of Montreal in 1982- 85 on the psychopharmacology of phenytoin after PhD (1979-1982) and MSc (1977-1979) studies concerning the effects of biogenic amines on learning. Since then, he has published in various subfields of psychopharmacology, mostly comprising exploratory activity in mice and rats as well as motor coordination and spatial learning.

Vladimir Lerner MD, PhD is Head of the Psychiatric Department in Be’er Sheva Mental Health Center (Israel) and Associate Professor of Psychiatry in Ben-Gurion University of the Negev. He emigrated from the former Soviet Union in 1990. The sphere of his scientific interest involves creativity and psychopathology, the treatment of schizophrenia and of tardive dyskinesia and the use of vitamins in psychiatry. He is the author of more than 120 scientific publications, 10 chapters and two edited books with coeditor C. Miodownik ‘New Hope for Mental Disturbances’ published by Nova Science Publishers Inc, New York, 2009 and ‘Vitamin D Deficiency’ published by Nova Science Publishers Inc, New York, 2011. He published together with Professor Witztum the books titled: ‘Genius and Madness – The complicated relationship between creativity and psychopathology’ (in Hebrew 2009) and ‘Genius and Insanity. Outlines concerning the analysis of the relationship between psychopathology and creativity as shown in the examples of separate individuals in Russia of the XIX century’ (in Russian 2011).

Dr. Heresco-Levy obtained a doctorate (M.D.) from Sackler School of Medicine, Tel Aviv University. Currently, he is full professor of psychiatry at Hadassah Medical School, Hebrew University, Jerusalem and serves as director of the psychiatry department at Herzog Memorial Hospital, Jerusalem. He is a member of the European College of Neuropsychopharmacology and Fellow of Collegium Internationale Neuro-Psychopharmacologicum. He conducted pioneer studies focusing on the role of glutamatergic neurotransmission in neuropsychiatric disorders, has published more than 150 scientific publications and is inventor of patents involving the use of NMDA receptor – based treatments for movement disorders, depression, and autoimmune types of encephalitis.

Dr Lolait obtained a Ph.D. degree from the Department of Pathology and Imuunology, Monash University in Melbourne, Australia in 1984, and was awarded a C.J.Martin Fellowship from the National Health and Medical Research Council of Australia to do postdoctoral work at the National Institute Mental Health (NIMH) in Bethesda, MD, USA. Dr Lolait spent about 11 years at NIMH, also supported by grants and fellowships from the McKnight and Stanley Foundations (USA), and as a Visiting Scientist. In 1997 he continued his studies at the University of Bristol, UK where he is currently a Senior Research Fellow in the School of Clinical Sciences. He has published over 100 scientific articles, principally on the cloning, expression, regulation and function of neuropeptide G protein-coupled receptors.

Dr. Kenneth Maiese is an internationally recognized physician-scientist whose investigations are designed to translate basic science into successful therapeutic treatments. He maintains therapeutic and scientific expertise in multiple areas that include translational medicine, neurology, neuroscience, oncology, immunology, diabetes, psychiatry, cardiovascular disease, renal disease, biomarkers, and epigenetics. Dr. Maiese graduated from the University of Pennsylvania Suma cum Laude with Distinction and was a Teagle Scholar, Grupe Scholar, and Joseph Collins Scholar at Weill Medical College of Cornell University. He trained as a physician-scientist at Cornell, the National Institutes of Health (NIH), and senior executive at the Harvard School of Public Health. Dr. Maiese has been fortunate to receive recognition with outstanding teaching awards and election to America's Top Physicians, and The Best of U.S. Physicians. He has extensive experience in academic medicine, healthcare delivery, the pharmaceutical industry, business management, and publishing.

Professor Mario Manto is a Neurologist at the CHU-Charleroi (Belgium). He is an expert in clinicalneurology, especiallycerebellardisorders. He is a Professor of Neuroanatomy at the University of Mons (Belgium). He isauthor or co-author of more than 170 peerreviewedscientific articles. He is editor of 7 books on cerebellardisorders.

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Juan Antonio Micó, is graduated in Medicine from the University of Cádiz (Spain) in 1981. Professor Micó obtained a doctorate PhD in Medical Sciences (1985, Cádiz, Spain) and another doctorate PhD in Biology Humaine Mention: Neuropsychopharmacology. (1998, University Pierre et Marie Curie, Paris, France)

He is Professor of Neuropsychopharmacology at the University of Cádiz (Spain) and Director of the Department of Neuroscience, Pharmacology and Psychiatry also Director of Spanish Mental Health Network (University of Cadiz Unit/Node G18), CIBER of Mental Health, CIBERSAM.

He has published 116 articles in JCR, reviews and book chapters related with the pharmacological mechanisms of action of psychopharmacological drugs.

Paula Moran received a PhD from the National University of Ireland, Galway. She spent six years as a senior scientist in the pharmaceutical industry at the Marion Merrell Dow Research Institute, Strasbourg, France and was involved in a number of drug discovery projects for Alzheimer's‐Disease and Schizophrenia. She was subsequently awarded a EU Human Capital and Mobility Fellowship at the Institute of Psychiatry, London, UK. Since then she has continued work on animal models of abnormal information processing in schizophrenia. She has received awards for research from the International Congress on Schizophrenia Research (ICOSR), British Association for Psychopharmacology (BAP) and Collegium Internationale Neuro‐ Psychopharmacologicum (CINP). She is preclinical external affairs officer of the British Association for Psychopharmacology (BAP) has been a member of the scientific advisory panel for psychotic disorders for the European College of Neuropsychopharmacology (ECNP).

Dr. Müller obtained a PhD in Psychology from the University of Düsseldorf, Germany.

He worked as a Senior Lecturer at the Institute of Psychiatry, King’s College London, UK, before he joined the Friedrich-Alexander-University of Erlangen-Nuremberg, Germany. Currently, he is Professor of Addiction Medicine. Dr. Müller has published more than 120 scientific papers and book chapters.

An Associate Professor of Biostatistics in the Department of Clinical Sciences at the University of Texas Southwestern Medical Center (UTSW). He also holds a secondary faculty appointment in the Department of Psychiatry at UTSW. Dr. Nakonezny has considerable experience in statistical methods and application of such methods to clinical research, including clinical trials, observational, and epidemiologic studies. His Field of expertise include Design and analysis of clinical studies and outcomes research.Statistical methodology in clinical trials, observational, and epidemiologic studies.Antipsychotic Medication Adherence.Clinical research spanning theory, methodology, and application mainly to brain illness in such patients (child/adolescent/adult) with Major Depressive Disorder (MDD), Schizophrenia, ADHD, and Substance Use Disorder. Dr. Nakonezny has collaborated on an array of funded projects spanning theory, methodology, and application mainly to brain illness in such patients with major depressive disorder, schizophrenia, and substance use disorder. His work has been published in a variety of prominent peer-reviewed scientific journals.

Dr. Nonogaki (MD, PhD) has worked as a Postdoc Research Fellow at the University of California, San Francisco and the Scripps Research Institute, La Jolla. He has studied central serotonin network in the regulation of appetite and energy homeostasis. Lorcaserin (Belviq), a selective 5-HT2C receptor agonist, which is used for the treatment of obesity, is based on the original research works by Dr. Nonogaki et al. Current studies are to determine the physiological mechanisms and potential treatment for obesity, type 2 diabetes and their complications. Dr. Nonogaki is also developing novel medical devices for hypertension and diabetes.

Klaus Peter Ossenkopp is Professor of Psychology and Neuroscience, Department of Psychology at Western University, London, Canada. His general research interests are in behavioral neuroscience with an emphasis on brain behavior relationships. These interests have been guided by psychological as well as a zoological perspectives, grounded in an evolutionary framework. His research program has focused on biological defense mechanisms related to dealing with environmental toxins or infectious agents at both the physiological as well as behavioral levels. He also has been interested in developing animal models of psychopathology, including rodent models of autism spectrum disorder.

Stefano Pallanti is Full Professor at the University of California Davis, Visiting Professor at Albert Einstein College of Medicine, Visiting Professor at Imperial College, London and Adjunct Associate Professor at Icahn School of Medicine at Mount Sinai, where he served as the Founder and Director of the Center of Excellence for OCD, Impulsive and Behavioural Addiction. He is Associate Professor of Psychiatry at the University of Florence in Italy where he has been Chair of Education and Director of the Residency Program of Psychiatr since 2010.

He is an Executive Committee Member and a Scientific Board Member of the ECNP(European College of Neuropsychopharmacology) and serves in its Educational Committee He is a member of the Editorial Board of the American Journal of Psychiatry and of the CNS Spectrums, where he is also a columnist and an International Editor. He is an International fellow member of American Psychiatric Publishing Inc.

George Perry (born April 12, 1953 in Lompoc, California) is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work in oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the Scrippss Institution of Oceanography at San Diego. He is distinguished as one of the top Alzheimer’s disease researchers by Expertscape with over 1000 publications, more than 66,000 citations (H=129), one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished University Chair in Neurobiology and is an active participant in many other scientific associations. He is an elected member of the Academies of Sciences of Mexico, Portugal, and Spain. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Disease which he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.

MP is Professor of Pharmacology at University of Milano (Italy). He was trained in Biochemistry/Cell Biology at University of Naples and received postdoctoral training at Int. Inst. Genet. Biophysics (Naples), and Dept. of Psychiatry at Washington University, (St. Louis, MO). His studies have contributed to characterization of cellular/molecular mechanisms involved in pathophysiology of neuropsychiatric disorders and psychotropic drug action. He received a NARSAD Independent Investigator Award, and funding from national and international agencies, including EU.

He is author of 120 publications, and currently field editor or editorial board member of neuropsychopharmacology/biological psychiatry journals.

Dr. Puri obtained his medical qualifications (M.A., M.B., B.Chir.) from St. John’s College, University of Cambridge and holds a doctorate (Ph.D.) from Imperial College London. He also holds undergraduate (B.Sc. (Hons) MathSci, DipStat, DipMath) and postgraduate (PG Dip Maths, M.Math.) qualifications in mathematics and is an Adjunct Professor in Neuroimaging and Spectroscopy at UL. He is a Fellow of the Royal College of Psychiatrists and a Fellow of the Royal Society of Biology. He has published more than 190 scientific publications. Dr. Puri is an Associate Editor of the journals BMC Psychiatry, BMC Research Notes (for Biochemistry, Medical Imaging, Neuroscience and Psychiatry), Medical Hypotheses, and Journal of Biomedical Graphics and Computing.

Mark M. Rasenick, Ph.D distinguished Professor of Physiology & Biophysics and Psychiatry University of Illinois Chicago, College of Medicine and Research Service, Jesse Brown VAMC.

Dr. Rasenick’s work has focused on G protein signaling in the nervous system. He has been particularly interested in how G proteins and the cytoskeleton work in concert to modify synaptic shape and to form a molecular basis for depression and the action of antidepressant drugs. He is also founder of Pax Neuroscience, a company designed to develop and utilize depression biomarkers for diagnostics, treatment and drug development. He is an elected fellow of the American College of Neuropsychopharmacology and the American Association for the Advancement of Science and the Cuban Academy of Sciences.

In addition to research and teaching, Dr. Rasenick is active in public policy. He currently chairs the Advocacy Committee for the American Brain Coalition. While a Robert Wood Johnson Fellow (1999-2000), he was a staff member with the late Senator Edward M. Kennedy, (D Mass.). He is also involved in international outreach for neuroscience.

Prof. Dr. Osman Sabuncuoglu has acquired his basic medical proficiency from the Medical School of Ankara University in 1992. He then completed his specialization in Child and Adolescent Psychiatry at the Medical School of Marmara University. He is the first consultant in his field from Turkey who has gained registration in UK via the application of Article 14, Medical Act.

He has identified the relationship between Traumatic Dental Injuries and suggested a descriptive model. He has made pioneering studies on mother-infant psychiatry. His scientific article where he summarized the contributions of Serefeddin Sabuncuoglu, was headlined on the cover of American Journal of Psychiatry. Osman Sabuncuoglu’s studies were backed by international “Donald Cohen Fellowship” for two times. Since psychiatric disorders in childhood are heavily interrelated, Dr. Sabuncuoglu carries out his scientific studies in all fields that may be relevant.

Dr. Frank M. Schmidt obtained his M.D. from University Leipzig, Germany, in 2010. Since 2017, he is board certified in Psychiatry and Psychotherapy with a focus on cognitive behavioural therapy. His main research areas are inflammatory and neurophysiological markers in the diagnosis and prediction of therapeutic response in affective disorders.

Dr. Shah obtained his medical degree (MD) from Gujarat University, India. Subsequently, he completed residency in psychiatry from Harlem Hospital Center, New York and fellowship in pain medicine from the University of Washington, Seattle. He also holds Masters in Public Health (MPH) from the University of Texas School of Public Health, Houston. Currently Dr. Shah is an assistant professor in the department of psychiatry & behavioral sciences at the University of Texas McGovern Medical School, Houston. He is currently a member of editorial board for CPSP, published by Bentham Science Publishers.

Dr. Tampi is a Professor of Psychiatry at Case Western Reserve University School of Medicine and the Vice Chairman for Education and Faculty Development, Residency Program Director and the Chief of Geriatric Psychiatry at MetroHealth, Cleveland, Ohio. Dr. Tampi also maintains his appointment as an Associate Clinical Professor of Psychiatry at Yale University School of Medicine. Dr. Tampi was a recipient of the American Association for Geriatric Psychiatry, 2013-Clinician of the Year Award. He is a Distinguished Fellow at the American Psychiatric Association. Dr. Tampi is the President of the International Medical Graduates (IMG) Caucus of the American Psychiatric Association.

Professor WK Tang was appointed to professor in the Department of Psychiatry, the Chinese University of Hong Kong in 2011. His main research areas are Addictions and Neuropsychiatry in Stroke. Professor Tang has published over 100 papers in renowned journals, and has also contributed to the peer review of 40 journals. He has secured over 20 major competitive research grants. He has served the editorial boards of five scientific journals. He was also a recipient of the Young Researcher Award in 2007, awarded by the Chinese University of Hong Kong.

I started working on the implication of postsynaptic density genes in the pathophysiology of neuropsychiatric diseases in 2002, first as a student, then as a resident student in psychiatry, studying the involvement of Homer family proteins in molecular responses to antipsychotic and psychotomimetic drugs, and their implication in the pathophysiology of the main psychiatric disorders (Schizophrenia, Major Depression, and Bipolar Disorder). In January 2010, I earned my Postgraduate Degree of Specialist in Psychiatry and Psychotherapy with honours, defending a thesis titled “Role of the Post-Synaptic Density Proteins in the mechanisms of action and side-effects of psychotropic drugs”.

Prof. Divya Vohora obtained her doctorate in Pharmacology in 2000 from Jamia Hamdard, New Delhi and is currently Professor of Pharmacology and In-charge of Pharmaceutical Medicine Programme in Faculty of Pharmacy. She is also Assistant Dean Students Welfare at Jamia Hamdard. She has 19 years of teaching/research experience with >100 publications in reputed national and international journals with >1100 citations. She has received grants and worked as Principal investigator for various research projects funded by AICTE, ICMR, UGC, CSIR and DST, Government of India. Thirty nine (M.Pharm: 29 and Ph.D: 10) degrees are awarded under her supervision. Her major areas of research interests are Neurobehavioral Pharmacology particularly epilepsy, neuropsychiatric diseases, cognitive functions, histamine and osteoporosis.

Vincent Van Waes graduated from the University of Lille, France, with a Master degree in Cognitive Science. He earned the PhD degree in Neuroscience from the University of Lille, France, in collaboration withthe Sapienza University of Roma, Italy, in 2008 (European Label). Following postdoctoral work at the Department of Cellular and Molecular Pharmacology of the Chicago Medical School, North Chicago, USA, he joined in 2010 the University of Bourgogne-Franche Comté, France as a Research Assistant Professor (Maître de Conférences) in the Laboratory of Integrative and Clinical Neuroscience and was appointed Professor in 2017.

Prof. Abraham Weizman obtained his MD degree from the Sackler Faculty of Medicine at Tel Aviv University in Israel and subsequently spent 2 years as a visiting scientist at NIMH in Bethesda, MD. He is a Professor of Adult and Child Psychiatry, the Head of the Research Unit at Geha Mental Health Center and Director of the Felsenstein Medical Research Center, all affiliated with the Sackler Faculty of Medicine, Tel Aviv University. Professor Weizman investigates brain mechanisms of mental disorders. In recent years he focuses on neurodevelopmental disorders, the development of new strategies for the treatment of psychotic disorders and psychopharmacology of mental disorders.

Dr. Robert Christian Wolf obtained his M.D. from Ulm University, Germany, and became board certified in Psychiatry and Psychotherapy in 2009. Currently, Dr. Wolf is Assistant Medical Director at the Department of General Psychiatry, Heidelberg University, where he is also head of the „Cognitive Neuropsychiatry” working group. He has published more than 150 scientific publications, with an internationally well-documented track record in behavioral neuropsychology and neuroimaging. Dr. Wolf is a member of several national and international professional and scientific associations and serves as an ad-hoc referee for internationally renowned journals within the field of clinical psychiatry and cognitive neuroscience.